Holen Sie sich die Stockscreener-App
5.465
4.00%
0.215
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
Verve Therapeutics Advances Heart Disease Gene Therapy Pipeline, Extends Cash Runway to 2027 - StockTitan
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire
Learn to Evaluate (VERV) using the Charts - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-05 | Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Grants New Employee RSU Awards Under 2024 Inducement Plan - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading 6.2% HigherWhat's Next? - MarketBeat
Franklin Resources Inc. Buys 5,914 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect - AccessWire
Geode Capital Management LLC Raises Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect | NDAQ:VERV | Press Release - Stockhouse Publishing
Barclays PLC Grows Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Barclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by Stifel Financial Corp - Defense World
State Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
State Street Corp Has $20.59 Million Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation - AccessWire
(VERV) Technical Pivots with Risk Controls - Stock Traders Daily
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - The Eastern Progress Online
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - The Eastern Progress Online
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
2024-12-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation - AccessWire
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k - Yahoo Finance
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online
Charles Schwab Investment Management Inc. Acquires 126,110 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out - AccessWire
2024-12-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out | NDAQ:VERV | Press Release - Stockhouse Publishing
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact The Gross Law Firm - Victoria Advocate
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com Australia
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Eastern Progress Online
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - The Eastern Progress Online
103,348 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Purchased by XTX Topco Ltd - MarketBeat
0.62%
5.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):